Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis

Arthritis Research and Therapy

Volumn 8, Issue 5, 2006, Pages

  Milner, Jennifer M ^a   Rowan, Andrew D ^a   Cawston, Tim E ^a   Young, David A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; COLLAGEN; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 16; METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL; BOVINAE; CARTILAGE; CYTOLOGY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; METABOLISM; NOSE SEPTUM; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; UPREGULATION;

ADAM PROTEINS; ANIMALS; CARTILAGE; CATTLE; COLLAGEN; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HOMEOSTASIS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; METALLOPROTEASES; NASAL SEPTUM; ORGAN CULTURE TECHNIQUES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; UP-REGULATION;

EID: 70249124544     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2034     Document Type: Article

References (53)

1. Goldring MB: The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000, 43:1916-1926.
2. Roughley PJ: Articular cartilage and changes in arthritis: noncollagenous proteins and proteoglycans in the extracellular matrix of cartilage. Arthritis Res 2001, 3:342-347.
3. Jones GC, Riley GA: ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Ther 2005, 7:160-169.
4. Porter S, Clark IM, Kevorkian L, Edwards DR: The ADAMTS metalloproteinases. Biochem J 2005, 386(Pt 1):15-27.
5. Struglics A, Larsson S, Pratta MA, Kumar S, Lark MW, Lohmander LS: Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments Osteoarthritis Cartilage 2006, 14:101-113.
6. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, et al.: Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644-648.
7. Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, Little CB, Last K, Farmer PJ, Campbell IK, et al.: ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005, 434:648-652.
8. Clark IM, Parker TE: Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets 2003, 7:19-34.
9. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim Biophys Acta 2000, 1477:267-283.
10. Ellis AJ, Curry VA, Powell EK, Cawston TE: The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor. Biochem Biophys Res Commun 1994, 201:94-101.
11. Gendron C, Kashiwagi M, Hughes C, Caterson B, Nagase H: TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors. FEBS Lett 2003, 555:431-436.
12. Kashiwagi M, Tortorella M, Nagase H, Brew K: TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001, 276:12501-12504.
13. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, Kitaura Y, Takai S, Sasahara RM, Horimoto A, et al.: Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 1998, 95:13221-13226.
14. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB, et al.: The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107:789-800.
15. Milner JM, Cawston TE: Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. Curr Drug Targets Inflamm Allergy 2005, 4:363-375.
16. Hollander AP, Pidoux I, Reiner A, Rorabeck C, Bourne R, Poole AR: Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J Clin Invest 1995, 96:2859-2869.
17. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y: Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997, 272 2446-2451.
18. Aimes RT, Quigley JP: Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 1995, 270:5872-5876.
19. Morgan TG, Rowan AD, Dickinson SC, Jones D, Hollander AP, Deehan D, Cawston TE: Human nasal cartilage responds to oncostatin M in combination with interleukin 1 or tumour necrosis factor alpha by the release of collagen fragments via collagenases. Ann Rheum Dis 2006, 65:184-190.
20. Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF, Spaull JR, Goldring MB, Koshy PJ, Rowan AD, et al.: The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 1998, 41:1760-1771.
21. Milner JM, Elliott SF, Cawston TE: Activation of procollagenases is a key control point in cartilage collagen degradation: Interaction of serine and metalloproteinase pathways. Arthritis Rheum 2001, 44:2084-2096.
22. Lewis EJ, Bishop J, Bottomley KM, Bradshaw D, Brewster M, Broadhurst MJ, Brown PA, Budd JM, Elliott L, Greenham AK, et al.: Ro 32-an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 1997, 121:540-546.
23. Ridley SH, Sarsfield SJ, Lee JC, Bigg HF, Cawston TE, Taylor DJ, DeWitt DL, Saklatvala J: Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: Regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol 1997, 158:3165-3173.
24. Dayer JM, Graham R, Russell G, Krane SM: Collagenase production by rheumatoid synovial cells: Stimulation by a human lymphocyte factor Science 1977, 195:181-183.
25. Rowan AD, Hui W, Cawston TE, Richards CD: Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model. Am J Pathol 2003, 162:1975-1984.
26. Mott JD, Werb Z: Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004, 16:558-564.
27. Koshy PJ, Lundy CJ, Rowan AD, Porter S, Edwards DR, Hogan A, Clark IM, Cawston TE: The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: A time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002, 46:961-967.
28. Barksby HE, Hui W, Wappler I, Peters HH, Milner JM, Richards CD, Cawston TE, Rowan AD: Interleukin-1 in combination with oncostatin M up-regulates multiple genes in chondrocytes: Implications for cartilage destruction and repair. Arthritis Rheum 2006, 54:540-550.
29. Koshy PJ, Rowan AD, Life PF, Cawston TE: 96-Well plate assays for measuring collagenase activity using (3)H-acetylated collagen. Anal Biochem 1999, 275:202-207.
30. Kevorkian L, Young DA, Darrah C, Donell ST, Shepstone L, Porter S, Brockbank SM, Edwards DR, Parker AE, Clark IM: Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 2004, 50:131-141.
31. Pratta MA, Yao W, Decicco C, Tortorella MD, Liu RQ, Copeland RA, Magolda R, Newton RC, Trzaskos JM, Arner EC: Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem 2003, 278 45539-45545.
32. Sugimoto K, Iizawa T, Harada H, Yamada K, Katsumata M, Takahashi M: Cartilage degradation independent of MMP/aggrecanases. Osteoarthritis Cartilage 2004, 12:1006-1014.
33. Mbvundula EC, Bunning RA, Rainsford KD: Arthritis and cannabinoids: HU-210 and Win-55, 212-2 prevent IL-1alpha-induced matrix degradation in bovine articular chondrocytes in-vitro. J Pharm Pharmacol 2006, 58:351-358.
34. Wada Y, Shimada K, Sugimoto K, Kimura T, Ushiyama S: Novel p38 mitogen-activated protein kinase inhibitor R-130823 protects cartilage by down-regulating matrix metalloproteinase- 1,-13 and prostaglandin E2 production in human chondrocytes. Int Immunopharmacol 2006, 6:144-155.
35. Caterson B, Flannery CR, Hughes CE, Little CB: Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol 2000, 19 333-344.
36. Little CB, Hughes CE, Curtis CL, Jones SA, Caterson B, Flannery CR: Cyclosporin A inhibition of aggrecanase-mediated prote oglycan catabolism in articular cartilage. Arthritis Rheum 2002, 46 124-129.
37. Patwari P, Gao G, Lee JH, Grodzinsky AJ, Sandy JD: Analysis of ADAMTS4 and MT4-MMP indicates that both are involved in aggrecanolysis in interleukin-1-treated bovine cartilage. Osteoarthritis Cartilage 2005, 13:269-277.
38. Tortorella MD, Malfait AM, Deccico C, Arner E: The role of ADAMTS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001, 9:539-552.
39. Young DA, Lakey RL, Pennington CJ, Jones D, Kevorkian L, Edwards DR, Cawston TE, Clark IM: Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther 2005, 7:R503-512.
40. Hui W, Barksby HE, Young DA, Cawston TE, McKie N, Rowan AD: Oncostatin M in combination with tumour necrosis factor (alpha) induces a chondrocyte membrane associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or -2. Ann Rheum Dis 2005, 64 1624-1632.
41. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ: Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J 1987, 248:265-268.
42. Knauper V, Wilhelm SM, Seperack PK, DeClerck YA, Langley KE, Osthues A, Tschesche H: Direct activation of human neutrophil procollagenase by recombinant stromelysin. Biochem J 1993, 295(Pt 2) 581-586.
43. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G: Biochemical characterization of human collagenase-3. J Biol Chem 1996, 271:1544-1550.
44. Cleaver CS, Rowan AD, Cawston TE: Interleukin 13 blocks the release of collagen from bovine nasal cartilage treated with proinflammatory cytokines. Ann Rheum Dis 2001, 60:150-157.
45. Wang X, Liang J, Koike T, Sun H, Ichikawa T, Kitajima S, Morimoto M, Shikama H, Watanabe T, Sasaguri Y, et al.: Overexpression of human matrix metalloproteinase-12 enhances the development of inflammatory arthritis in transgenic rabbits. Am J Pathol 2004, 165:1375-1383.
46. Liu M, Sun H, Wang X, Koike T, Mishima H, Ikeda K, Watanabe T, Ochiai N, Fan J: Association of increased expression of macrophage elastase (matrix metalloproteinase 12) with rheumatoid arthritis. Arthritis Rheum 2004, 50:3112-3117.
47. Yamanaka H, Makino K, Takizawa M, Nakamura H, Fujimoto N, Moriya H, Nemori R, Sato H, Seiki M, Okada Y: Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in rheumatoid synovium. Lab Invest 2000, 80:677-687.
48. van der Zee E, Everts V, Beertsen W: Cytokine-induced endogenous procollagenase stored in the extracellular matrix of soft connective tissue results in a burst of collagen breakdown following its activation J Periodontal Res 1996, 31:483-488.
49. Milner JM, Rowan AD, Elliott SF, Cawston TE: Inhibition of furinlike enzymes blocks interleukin-1alpha/oncostatin M-stimulated cartilage degradation. Arthritis Rheum 2003, 48:1057-1066.
50. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61-65.
51. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M: Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP -2 FEBS Lett 1996, 393:101-104.
52. Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW, Wang J, Cao Y, Tryggvason K: Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000, 97:4052-4057.
53. Gebauer M, Saas J, Sohler F, Haag J, Soder S, Pieper M, Bartnik E, Beninga J, Zimmer R, Aigner T: Comparison of the chondrosarcoma cell line SW1353 with primary human adult articular chondrocytes with regard to their gene expression profile and reactivity to IL-1beta. Osteoarthritis Cartilage 2005, 13:697-708.